97 related articles for article (PubMed ID: 8048398)
1. Phase I trial of combined recombinant interleukin-2 with levamisole in patients with advanced malignant disease.
Call TG; Creagan ET; Frytak S; Buckner JC; van Haelst-Pisani C; Homburger HA; Katzmann JA
Am J Clin Oncol; 1994 Aug; 17(4):344-7. PubMed ID: 8048398
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of combined levamisole with recombinant interleukin-2 in patients with advanced malignant melanoma.
Creagan ET; Rowland KM; Suman VJ; Kardinal CG; Marschke RF; Marks RS; Maples WJ
Am J Clin Oncol; 1997 Oct; 20(5):490-2. PubMed ID: 9345334
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.
Farace F; Mathiot C; Brandely M; Tursz T; Dorval T; Pouillart P; Triebel F; Hercend T; Fridman WH
Clin Exp Immunol; 1990 Nov; 82(2):194-9. PubMed ID: 2122928
[TBL] [Abstract][Full Text] [Related]
5. Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level.
Sano T; Saijo N; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Sakurai M; Takahashi H; Nakano H; Nakagawa K
Jpn J Cancer Res; 1988 Jan; 79(1):131-43. PubMed ID: 3128501
[TBL] [Abstract][Full Text] [Related]
6. Combined levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma: a phase II study.
Creagan ET; Hestorff RD; Suman VJ; Mailliard JA; Nair S; Krook JE; Kugler JW; Marschke RF; Michalak JC; Tschetter LK
Am J Clin Oncol; 1998 Apr; 21(2):139-41. PubMed ID: 9537198
[TBL] [Abstract][Full Text] [Related]
7. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
[TBL] [Abstract][Full Text] [Related]
8. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
9. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study.
Atzpodien J; Körfer A; Evers P; Franks CR; Knüver-Hopf J; Lopez-Hänninen E; Fischer M; Mohr H; Dallmann I; Hadam M
Mol Biother; 1990 Mar; 2(1):18-26. PubMed ID: 2334534
[TBL] [Abstract][Full Text] [Related]
10. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine.
McMahon DK; Armstrong JA; Huang XL; Rinaldo CR; Gupta P; Whiteside TL; Pazin GJ; Tripoli C; Ho M
AIDS; 1994 Jan; 8(1):59-66. PubMed ID: 8011237
[TBL] [Abstract][Full Text] [Related]
12. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity.
Caligiuri MA; Murray C; Soiffer RJ; Klumpp TR; Seiden M; Cochran K; Cameron C; Ish C; Buchanan L; Perillo D
J Clin Oncol; 1991 Dec; 9(12):2110-9. PubMed ID: 1960552
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
14. A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.
Ahmed FY; Leonard GA; A'Hern R; Taylor AE; Lorentzos A; Atkinson H; Moore J; Nicolson MC; Riches PG; Gore ME
Br J Cancer; 1996 Oct; 74(7):1109-13. PubMed ID: 8855983
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion.
Kohler PC; Hank JA; Moore KH; Storer B; Bechhofer R; Hong R; Sondel PM
Cancer Invest; 1989; 7(3):213-23. PubMed ID: 2790538
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of interleukin-2 in children with cancer and evaluation of clinical and immunologic status during therapy. A Pediatric Oncology Group Study.
Nasr S; McKolanis J; Pais R; Findley H; Hnath R; Waldrep K; Ragab AH
Cancer; 1989 Aug; 64(4):783-8. PubMed ID: 2787201
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer.
Urba WJ; Steis RG; Longo DL; Kopp WC; Maluish AE; Marcon L; Nelson DL; Stevenson HC; Clark JW
Cancer Res; 1990 Jan; 50(1):185-92. PubMed ID: 2293554
[TBL] [Abstract][Full Text] [Related]
19. A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.
Creekmore SP; Harris JE; Ellis TM; Braun DP; Cohen II; Bhoopalam N; Jassak PF; Cahill MA; Canzoneri CL; Fisher RI
J Clin Oncol; 1989 Feb; 7(2):276-84. PubMed ID: 2783732
[TBL] [Abstract][Full Text] [Related]
20. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
